Motoi Odani

Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study

Eizo Watanabe, Osamu Nishida, Yasuyuki Kakihana et al. · Shock · 2019 · 66 citations · Full text

Pharmacy, Immunology, Pharmacology +17

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients

Masafumi Fukagawa, Keitaro Yokoyama, Takashi Shigematsu et al. · Nephrology Dialysis Transplantation · 2016 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism

Takashi Shigematsu, Masafumi Fukagawa, Keitaro Yokoyama et al. · Clinical and Experimental Nephrology · 2017 · 29 citations

Medicine, Endocrinology, Nephrology +15

A randomized controlled phase <scp>II</scp> clinical trial comparing <scp>ONO</scp>‐4053, a novel <scp>DP</scp>1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis

Kimihiro Okubo, Kazuhiro Hashiguchi, Takumi Takeda et al. · Allergy · 2017 · 19 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study

Takashi Shigematsu, Masafumi Fukagawa, Keitaro Yokoyama et al. · Clinical Therapeutics · 2018 · 19 citations · Full text

Medicine, Endocrinology, Nephrology +17